Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTFields + pembrolizumab
- Development stage
- Unknown
- Lead developer
- NovoCure
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Topical (device Applied To Skin Using Electrodes), Intravenous
01
Overview
TTFields + pembrolizumab is a combination regimen that includes Tumor Treating Fields (TTFields), a noninvasive regional therapy delivering low-intensity, alternating electric fields via surface electrodes (Optune device), and pembrolizumab, a programmed death-1 (PD-1) checkpoint inhibitor monoclonal antibody (Keytruda). TTFields disrupt mitosis by interfering with mitotic spindle formation and induce immunogenic cell death, activating type-1 interferon pathways and inflammasomes (notably STING and AIM2). Pembrolizumab blocks PD-1 on T cells, enhancing antitumor immune responses. Together, preclinical and early clinical data indicate synergistic efficacy, with TTFields amplifying immune activation and pembrolizumab enabling more sustained, effective antitumor immunity. This combination is under clinical investigation for newly diagnosed glioblastoma and advanced/metastatic NSCLC, improving survival outcomes and demonstrating acceptable tolerability[3][5][7][4][6].
- Brand names
- Optune + Keytruda
- Other names
- tumor treating fields + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on TTFields + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTFields + pembrolizumab.